CN115006431A - Application of poecilobdella manillensis in preparing medicine for treating leucoderma and medicinal preparation - Google Patents
Application of poecilobdella manillensis in preparing medicine for treating leucoderma and medicinal preparation Download PDFInfo
- Publication number
- CN115006431A CN115006431A CN202210947163.5A CN202210947163A CN115006431A CN 115006431 A CN115006431 A CN 115006431A CN 202210947163 A CN202210947163 A CN 202210947163A CN 115006431 A CN115006431 A CN 115006431A
- Authority
- CN
- China
- Prior art keywords
- poecilobdella manillensis
- manillensis
- poecilobdella
- treatment
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of vitiligo treatment, and discloses application of poecilobdella manillensis in preparing a medicament for treating vitiligo and a medicinal preparation. The invention provides a new application of poecilobdella manillensis in preparing a medicament for treating leucoderma, provides a new natural medicament for treating intractable diseases leucoderma, and has good treatment effect on the leucoderma.
Description
Technical Field
The invention relates to the technical field of vitiligo treatment, and in particular relates to application of poecilobdella manillensis in preparing a medicament for treating vitiligo and a medicinal preparation.
Background
Vitiligo, also known as white erosion and vitiligo, is a systemic skin disease caused by acquired melanocyte idiopathic damage and abnormal function leading to depigmentation, and is mainly characterized in that melanocytes fall off from epidermis to form white spots. Vitiligo is a skin disease affecting the appearance of people, and the disease is painless and itchy. Recent medical studies have demonstrated that vitiligo patients have poor ultraviolet protection and skin cancer incidence rates much higher than normal. Moreover, vitiligo can also induce various diseases, such as pernicious anemia, alopecia areata, psoriasis, malignant tumor, bronchial asthma, rheumatoid arthritis, cataract and hyperthyroidism.
At present, the cause of vitiligo is not clear, and studies suggest that the following factors may be involved: the genetic theory is shown; the theory of autoimmunity; the theory of psychology and neurochemistry; the theory of melanocyte self destruction; fifth, the theory of trace element deficiency. Vitiligo occurs all over the world, the incidence rate of india is the highest, nearly ten million people occur in China, the incidence rate is about 1% -2%, and the vitiligo has low incidence rate of generally light skin color and high incidence rate of dark skin color regardless of race, sex and the like.
In clinic, the treatment is usually performed by narrow spectrum medium wave ultraviolet (NB-UVB) UVB, 308 nm excimer laser, calcineurin inhibitors (tacrolimus and pimecrolimus), glucocorticoids, traditional Chinese medicine methods, medicines and the like. But the effect is not ideal, and patients are often treated for a long time and are difficult to cure. The main reason is the lack of effective treatment drugs, and the treatment mainly aims at relieving symptoms and cannot completely cure the symptoms. Therefore, for the intractable disease vitiligo, the exploration and the search of effective treatment medicines have profound and important significance.
Poecilobdella manillensis (Poecilobel la manillensis Lesson) is Poecilobdella manillensis of Poecilobdellida of Arecilobdellida of Ancisdellida of Anetholophylum, and has multiple pharmacological effects of softening blood vessel, resisting coagulation, resisting thrombus and dissolving thrombus, resisting platelet aggregation, reducing blood fat, promoting uric acid excretion, resisting inflammation, resisting cancer and the like. Can be used for treating carotid artery plaque, systemic arterial plaque, myocardial infarction, cerebral hemorrhage, coronary atherosclerotic heart disease, angina pectoris, atherosclerosis, gout, diabetic nephropathy, diabetic peripheral neuropathy, retinal hemorrhage, diabetes, etc. However, no report on the treatment of leucoderma by poecilobdella manillensis is available.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the application of poecilobdella manillensis in preparing the medicine for treating leucoderma and the pharmaceutical preparation, and the medicine can effectively treat the leucoderma which is difficult to treat.
In order to achieve the above purpose, the invention provides an application of poecilobdella manillensis in preparing a medicament for treating vitiligo.
Preferably, the method of treatment of the medicament comprises at least one of oral treatment and topical treatment.
Preferably, the medicine is taken at a dose of 0.1-3 g/day.
Preferably, the antithrombin activity of the poecilobdella manillensis is higher than 200U/g.
The invention provides a pharmaceutical preparation for treating leucoderma, which comprises the raw material components of Poecilobdella manillensis.
Preferably, the poecilobdella manillensis is provided in the form of at least one of freeze-dried poecilobdella manillensis powder, salivary secretion of the poecilobdella manillensis and an extract of the poecilobdella manillensis.
Preferably, the raw material components of the pharmaceutical preparation also contain fructus psoraleae.
Preferably, the raw material components of the pharmaceutical preparation further comprise pseudo-ginseng, emblic leafflower fruit and longan.
Preferably, the pharmaceutical preparation further comprises pharmaceutically acceptable auxiliary materials.
Preferably, the auxiliary material is selected from at least one of sodium carboxymethylcellulose, glycerol, ethylparaben, laurocapram, polyethylene glycol 400, polyethylene glycol 4000, stearic acid, paraffin and silicone cream.
The invention provides a new application of poecilobdella manillensis in preparing a medicament for treating leucoderma, provides a new natural medicament for treating intractable diseases leucoderma, and has good treatment effect on the leucoderma.
Drawings
FIG. 1 is a chart of leukoplakia before treatment of patients with vitiligo in a typical case of the present invention;
FIG. 2 is a graph showing the white spot pattern after the treatment of patients with vitiligo in the typical case of the present invention.
Detailed Description
The following detailed description of embodiments of the invention refers to the accompanying drawings. It should be understood that the detailed description and specific examples, while indicating the present invention, are given by way of illustration and explanation only, not limitation.
The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value, and such ranges or values should be understood to encompass values close to those ranges or values. For ranges of values, between the endpoints of each of the ranges and the individual points, and between the individual points may be combined with each other to give one or more new ranges of values, and these ranges of values should be considered as specifically disclosed herein.
It should be noted that technical solutions between the respective embodiments may be combined with each other, but it must be based on the realization of the technical solutions by those skilled in the art, and when the technical solutions are contradictory to each other or cannot be realized, such a combination of technical solutions should not be considered to exist, and is not within the protection scope of the present invention.
The invention provides application of poecilobdella manillensis in preparing a medicament for treating leucoderma.
In the invention, researches show that the medicament prepared from the poecilobdella manillensis as the raw material has the effect of treating leucoderma, has obvious medicinal effect, provides new application for the poecilobdella manillensis, and provides a new natural medicament for treating leucoderma which is an intractable disease.
In a preferred embodiment, in the medicament, the poecilobdella manillensis is in the form of at least one of freeze-dried poecilobdella manillensis powder, salivary secretion of poecilobdella manillensis, and poecilobdella manillensis extract. The Poecilobdella manillensis freeze-dried powder or the Poecilobdella manillensis salivary secretion or the Poecilobdella manillensis extract can be directly used as a medicament, and can also be used as one of the components to be prepared into the medicament together with other auxiliary materials (such as a preservative, an excipient, a flavoring agent and the like) or medicinal components (such as fructus psoraleae and the like).
The main active component of the freeze-dried poecilobdella manillensis powder is hirudin which is the strongest natural anticoagulant substance in the world at present, and the hirudin directly acts on thrombin and is effective on thrombus which is formed and is formed. Meanwhile, the poecilobdella manillensis also contains fibrinolysin, hyaluronidase and the like, and can also decompose fibrin in thrombus. Has excellent thrombolysis and fiber dissolving effects. In addition, hirudin has the advantage that it is not destroyed by oral administration.
More preferably, in the medicament, the antithrombin activity of the poecilobdella manillensis is higher than 200U/g.
In the invention, the treatment method of the medicine comprises at least one of oral treatment and external treatment, namely, the medicine can adopt an oral treatment mode, an external treatment mode or an oral and external combined treatment mode.
Wherein, when the medicine is taken orally, the dosage form of the medicine comprises powder, capsules, tablets, liquid preparations, granules or decoction, and when the medicine is taken externally, the dosage form of the medicine comprises ointment or liquid preparations. The above-mentioned drugs in various dosage forms can be prepared by conventional methods in the pharmaceutical field, and are not specifically limited herein. In addition, the dosage form of the drug is not limited thereto, and those skilled in the art will recognize that feasible dosage forms are within the scope of the present invention.
In order to make the therapeutic effect of the drug on vitiligo more effective, in the present invention, a plurality of dosage forms can be used in combination, for example, powder and decoction can be taken simultaneously, powder and ointment can be taken simultaneously, or powder and external liquid preparation can be used simultaneously.
In a preferred embodiment, the medicament is administered in an amount of 0.1 to 3 g/day. It will be appreciated that the dose is calculated as the amount of freeze-dried poecilobdella manillensis powder and/or poecilobdella manillensis extract and/or poecilobdella manillensis salivary secretion in the medicament.
The invention also provides a pharmaceutical preparation for treating leucoderma, which comprises the raw material components of Poecilobdella manillensis.
Further, the Poecilobdella manillensis is provided in the form of at least one of Poecilobdella manillensis freeze-dried powder, Poecilobdella manillensis salivary secretion and Poecilobdella manillensis extract.
In a specific embodiment, the pharmaceutical preparation is freeze-dried poecilobdella manillensis powder.
In one embodiment, the raw material components of the pharmaceutical preparation further comprise fructus psoraleae. Psoralea corylifolia (scientific name: Psoralea coriylifolia Linn.) is also known: fructus psoraleae, platane and semen allii tuberosi have the effects of tonifying kidney and strengthening yang, and tonifying spleen and invigorating stomach, can treat skin diseases such as psoriasis and the like, and further improves the treatment effect of the medicinal preparation on leucoderma by adding the fructus psoraleae.
In a preferred embodiment, the raw material components of the pharmaceutical preparation further comprise notoginseng, emblic leafflower fruit and longan. More preferably, the raw material components of the pharmaceutical preparation are freeze-dried poecilobdella manillensis powder, pseudo-ginseng, emblic leafflower fruit and longan, and the weight ratio of the freeze-dried poecilobdella manillensis powder to the pseudo-ginseng to the emblic leafflower fruit to the longan is 1-9: 10-60: 5-20: 30-80 parts. Further, in a specific embodiment, the preparation method of the pharmaceutical preparation comprises: 1 g-9 g of poecilobdella manillensis freeze-dried powder, 10-60 g of pseudo-ginseng, 5-20 g of emblic leafflower fruit and 30-80 g of longan are percolated, soaked or ultrasonically extracted by 1000-1200 mL of edible ethanol or white spirit (20-40 degrees), refrigerated or frozen for 1-3 days and then filtered to obtain liquid, namely the pharmaceutical preparation.
In a specific embodiment, the pharmaceutical preparation further comprises pharmaceutically acceptable auxiliary materials, wherein the auxiliary materials can be flavoring agents, and can also be materials used in the preparation process, such as diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants and the like.
Further, in the present invention, the auxiliary material is at least one selected from the group consisting of sodium carboxymethylcellulose, glycerin, ethylparaben, laurocapram, polyethylene glycol 400 (PEG 400), polyethylene glycol 4000 (PEG 4000), stearic acid, paraffin, and silicone cream.
In a specific embodiment, the method of preparing the pharmaceutical formulation comprises: drying in the shade, air drying, freeze drying, salting out, ultrafiltering, gel filtering, isoelectric precipitation, ion exchange chromatography, affinity chromatography, adsorption chromatography, reverse flow dissolution, decocting, and enzymolysis.
The present invention will be described in detail below by way of examples, but the scope of the present invention is not limited thereto.
In the following embodiments, the freeze-dried poecilobdella manillensis powder is provided by Yunnan Sanjiang herbal medicine limited company, and the antithrombin activity of the freeze-dried poecilobdella manillensis powder is more than or equal to 200U; similarly, the dosage of the saliva of Poecilobdella manillensis or other Poecilobdella manillensis extract requires that the antithrombin activity is more than or equal to 200U. In addition, the experimental methods in the following examples are all conventional in the art unless otherwise specified. The experimental materials used in the following examples are all commercially available products unless otherwise specified.
Example 1
The medicinal preparation for treating leucoderma comprises the following raw material components: the medicinal preparation is oral lyophilized powder of Poecilobdella manillensis.
Example 2
The medicinal preparation for treating leucoderma comprises the following raw material components: the medicinal preparation comprises Poecilobdella manillensis (lyophilized Poecilobdella manillensis powder) and fructus Psoraleae, wherein the medicinal preparation is oral lyophilized Poecilobdella manillensis powder and fructus Psoraleae decoction;
the preparation method of the fructus psoraleae decoction comprises the following steps: adding water (12 g per 300 mL), soaking for 20 min, boiling for 30 min, decocting for 2 times, mixing the decoctions, and concentrating to 1/3.
Example 3
The medicinal preparation for treating leucoderma comprises the following raw material components: poecilobdella manillensis (saliva extract of Poecilobdella manillensis), fructus psoraleae (fructus psoraleae extract), laurocapram, glycerol, sodium carboxymethylcellulose and ethylparaben, wherein the pharmaceutical preparation is external Poecilobdella manillensis ointment;
the preparation method of the poecilobdella manillensis ointment comprises the following steps: sequentially adding glycerol, sodium carboxymethylcellulose and ethylparaben into water under stirring, and uniformly mixing to obtain a hydrogel matrix, wherein the dosage ratio of the glycerol to the sodium carboxymethylcellulose to the ethylparaben to the water is 14g:6g:0.2g:80 mL; adding the hirudo poecilobii saliva extract, the fructus psoraleae extract and the laurocapram into the hydrogel matrix, and uniformly mixing to obtain a hirudo poecilobii ointment; wherein the weight ratio of the glycerol to the saliva extract of the Poecilobdella manillensis to the fructus psoraleae extract to the laurocapram is 14:0.5:6: 1.
Example 4
The medicinal preparation for treating leucoderma comprises the following raw material components: the medicinal preparation is lyophilized powder of Poecilobdella manillensis, and can be oral lyophilized powder of Poecilobdella manillensis and external liquid preparation;
the preparation method of the liquid preparation comprises the following steps: adding the freeze-dried poecilobdella manillensis powder into water, and uniformly mixing to obtain the external liquid preparation, wherein the dosage ratio of the freeze-dried poecilobdella manillensis powder to the water is 5g:100 mL.
Example 5
The medicinal preparation for treating leucoderma comprises the following raw material components: poecilobdella manillensis (saliva extract of Poecilobdella manillensis), fructus psoraleae (fructus psoraleae extract), laurocapram, PEG400 and PEG4000, wherein the pharmaceutical preparation is external Poecilobdella manillensis ointment;
the preparation method of the poecilobdella manillensis ointment comprises the following steps: heating and melting PEG400 and PEG4000, and cooling under stirring to obtain ointment matrix, wherein the weight ratio of PEG400 to PEG4000 is 30: 40; adding the hirudo poecilobii saliva extract, the fructus psoraleae extract and the laurocapram into the ointment matrix, and uniformly mixing to obtain the hirudo poecilobii ointment, wherein the weight ratio of the hirudo poecilobii saliva extract, the fructus psoraleae extract, the laurocapram and the PEG400 is 0.5:7:1: 30.
Example 6
The pharmaceutical preparation for treating leucoderma comprises raw material components of poecilobdella manillensis (saliva extract of poecilobdella manillensis), fructus psoraleae (fructus psoraleae extract), laurocapram, stearic acid, paraffin, liquid paraffin and glycerol, and the pharmaceutical preparation is external poecilobdella manillensis ointment;
the preparation method of the poecilobdella manillensis ointment comprises the following steps: heating and melting stearic acid, paraffin and liquid paraffin, adding glycerol under stirring in an emulsifying machine, and mixing uniformly to obtain an ointment matrix, wherein the weight ratio of the stearic acid to the paraffin to the liquid paraffin to the glycerol is 20:20:35: 15; adding the hirudo poecilobii saliva extract, the fructus psoraleae extract and the laurocapram into the ointment matrix, and uniformly mixing to obtain the hirudo poecilobii ointment, wherein the weight ratio of the hirudo poecilobii saliva extract, the fructus psoraleae extract, the laurocapram and the stearic acid is 0.3:6:1: 20.
Example 7
The raw material components of the pharmaceutical preparation for treating leucoderma are poecilobdella manillensis (freeze-dried poecilobdella manillensis powder) and silicon cream, and the pharmaceutical preparation is external poecilobdella manillensis ointment;
the preparation method of the poecilobdella manillensis ointment comprises the following steps: adding silicon cream into the lyophilized poecilobdella manillensis powder to prepare ointment, wherein the weight ratio of the lyophilized poecilobdella manillensis powder to the silicon cream is 0.5: 40.
Example 8
The raw material components of the medicinal preparation for treating leucoderma comprise Poecilobdella manillensis, pseudo-ginseng, emblic leafflower fruit and longan, and the medicinal preparation is an oral Poecilobdella manillensis liquid preparation;
the preparation method of the poecilobdella manillensis liquid preparation comprises the following steps: soaking Hirudo powder, Notoginseng radix, fructus Phyllanthi and arillus longan in 38% (v/v) Chinese liquor for 3-5 days, filtering, freezing the filtrate at 18 deg.C for 2 days, and filtering to obtain liquid preparation; wherein the dosage ratio of the poecilobdella manillensis freeze-dried powder to the pseudo-ginseng to the emblic leafflower fruit to the longan to the white spirit is 3g to 30g to 14g to 50g to 1100 mL.
Firstly, the lyophilized poecilobdella manillensis powder obtained in example 1 and the poecilobdella manillensis ointment obtained in example 5 are subjected to pharmacodynamic experiments for treating leucoderma, and the method and the results are as follows:
1. material
1.1 experimental equipment, instruments:
one in ten thousand electronic balances and one in hundredth electronic balances; a multifunctional microplate reader; ultramicro ultraviolet-visible spectrophotometer.
1.2 drugs and reagents: bovine fibrinogen; thrombin.
1.3 Experimental animals: male C57BL/6 mice, body weight (20. + -.2) g.
2. Method of producing a composite material
2.1 Experimental grouping and modeling:
70C 57BL/6 mice were randomly divided into 7 groups: normal group, model group, 5 treatment groups, wherein 5 treatment groups comprise 1 treatment group (poecilobdella manillensis ointment group), 2 treatment groups (low-dose poecilobdella manillensis freeze-dried powder + ointment group), 3 treatment groups (medium-dose poecilobdella manillensis freeze-dried powder + ointment group), 4 treatment groups (high-dose poecilobdella manillensis freeze-dried powder + ointment group) and 5 treatment groups (medium-dose poecilobdella manillensis freeze-dried powder group).
Each group of mice had hair removed from an area of the back of approximately 2 cm by 2 cm. After 1 week of depilation, the backs of C57BL/6 mice were smeared with 2.5% hydroquinone to establish a C57BL/6 mouse vitiligo model. Groups of mice were treated as follows: normal group: applying polyethylene glycol ointment (60% polyethylene glycol 400 and 40% polyethylene glycol 4000, mixing, heating to 65 deg.C for melting, and condensing) on the back for 60 days; model group: applying 2.5% hydroquinone ointment (prepared from 2.5% hydroquinone ointment including 2.5 g hydroquinone, 58.5g polyethylene glycol 400 and 39g polyethylene glycol 4000), heating to 65 deg.C, melting, and condensing for 60 days; poecilobdella manillensis treatment group: smearing 2.5% hydroquinone ointment (prepared from 2.5% hydroquinone ointment: 2.5 g hydroquinone, 58.5g polyethylene glycol 400 and 39g polyethylene glycol 4000, heating to 65 deg.C, melting, and condensing) on back for 60d, and smearing 1 group to 4 groups of the ointment prepared in example 5 when 2.5% hydroquinone ointment is smeared at 21d, and drenching 2-5 groups with lyophilized powder solution of Poecilobdella manillensis (prepared from lyophilized powder solution of Poecilobdella manillensis, 13g of lyophilized powder of Poecilobia manillensis, and 37g of purified water to obtain suspension, wherein the low dose group is drenching 0.25mL each time, the medium dose group is drenching 0.5mL each time, and the high dose group is drenching 1mL each time for 1 time each time), and continuously administering 40d (once a day). The normal group and the model group were also given the same dose of physiological saline at the ointment application 21 d. After 2h of the last administration, the skin of the back where the ointment is applied is collected and fixed in 10% formalin.
2.2 test indexes
2.2.1 mouse skin Melanin-containing Hair follicle count:
the skin tissue fixed in 10% formalin solution was HE-stained, and the skin tissue was observed under an optical microscope to count the number of hair follicles. Under 200 times of the mirror, 6 areas were randomly selected, and the total number of follicles and the number of follicles containing black color in each area were recorded, and counted as the number of follicles containing melanin out of 100 follicles.
2.2.2 assay of basal layer melanocytes:
the skin tissue fixed in 10% formalin solution was washed with running water for 3-4 min. After washing, putting skin tissues into 0.1% dihydroxyphenylalanine (prepared by 0.1 mol/L phosphate buffer solution), and putting the skin tissues into an oven at 37 ℃ for 1 h; removing dihydroxyphenylalanine, replacing with fresh 0.1% dihydroxyphenylalanine, and placing in oven at 37 deg.C for 12 hr; washing with running water for 10 min; fixing the tissue with Bouin's solution for 24 h; the tissue was rinsed with running water for 4 h. After completion of the above procedure, the skin tissue was subjected to conventional paraffin-embedded sectioning and HE staining. The melanocytes were stained brown-black under an optical microscope. Under a 200-fold mirror, 6 areas are randomly selected, the number of epidermal basal cells and the number of melanocytes of each area are recorded, and finally the number of melanocytes of each 100 epidermal basal cells is counted.
2.2.3 determination of epidermal cells containing melanin granules:
skin tissues fixed in 10% formalin were subjected to routine paraffin-embedded sections and subjected to Lillie ferrous sulfate staining. The operation is as follows: putting the slices into a mixed solution of ferric chloride and potassium ferricyanide for dip dyeing for 20 min; differentiating with 1% acetic acid for 30 s; washing with distilled water for 3 times, rapidly dehydrating with 95% ethanol and anhydrous ethanol, and sealing with neutral gum. Mellie staining was positive with dark green melanin. Under a 200-fold mirror, 6 areas were randomly selected, the number of epidermal basal cells and the number of basal cells containing melanin granules were recorded for each area, and finally the number of basal cells containing melanin granules was counted for every 100 epidermal basal cells.
3. The test results are shown in table 1 below:
TABLE 1
As can be seen from table 1, the number of melanin follicles, the number of basal layer melanocytes and the number of melanocyte-containing epidermal cells in the skin of the model group mice were significantly reduced as compared with the normal group, and there was a significant difference (P < 0.01) from the normal group. Each treatment group can significantly increase the number of melanin hair follicles, basal layer melanocytes and melanocyte-containing epidermal cells in the skin of mice, and has significant difference from the model group (P < 0.05).
Secondly, the pharmaceutical formulations prepared in the examples were tested as follows:
1. clinical data: 150 patients with vitiligo with confirmed diagnosis are selected and randomly divided into 3 groups, wherein 23 male patients and 27 female patients in a control group have the minimum age of 18 years, the maximum age of 60 years, the average age of 32.25 +/-11.07 years, 17 patients with the course of disease within 1 year, 14 patients with 1-3 years and 19 patients with more than 3 years. 21 men and 29 women in 1 group are treated, the minimum age is 19 years old, the maximum age is 60 years old, the average age is 33.22 +/-10.58, the course of the disease is within 1 year and 15, 19 in 1-3 years and 16 above 3 years. The treatment is carried out on 24 men and 26 women in 2 groups, wherein the minimum age is 19 years old, the maximum age is 62 years old, the average age is 31.52 +/-10.03, the disease course is 13 within 1 year, 20 cases in 1-3 years, and 17 cases over 3 years. The difference of sex, age, disease course and disease degree of the three groups of patients is not significant (P > 0.05).
2. The treatment method comprises the following steps:
control group: methylprednisolone tablets (trade name: meluole; manufacturing company: Pfizer Italia srl.; specification: 4mg × 30 s) are used for treatment, 1 time 4mg, and 1 time 1 day. 1 month is 1 course of treatment, and after each course of treatment, it is determined whether to continue administration according to the state of illness, and at most 3 courses of treatment are performed.
Treatment 1 group: the lyophilized poecilobdella manillensis powder (specification 0.3 g/bottle) described in example 1 was used for treatment 1 time, 1 bottle, and 3 times a day. 1 month is 1 course of treatment, and after each course of treatment, it is determined whether to continue administration according to the state of illness, and at most 3 courses of treatment are performed.
Treatment 2 groups: the Poecilobdella manillensis ointment prepared in example 5 was applied to the affected part for 3 times 1 day. 1 month is 1 course of treatment, and after each course of treatment, it is determined whether to continue administration according to the state of illness, and at most 3 courses of treatment are performed.
3. The evaluation standard of the curative effect is as follows: firstly, healing: clinical symptoms disappear, and the white spot disappearance rate is more than or equal to 95 percent. Secondly, effect is displayed: the clinical symptoms mostly disappear, and the white spot disappearance rate is more than or equal to 50 percent and is more than 95 percent. ③ effective: the clinical symptoms are improved or partially disappeared, and the white spot disappearance rate is more than or equal to 30 percent when the ratio is more than 50 percent. Fourthly, invalidation: the white spots are unchanged or the disappearance rate is less than 30 percent.
4. The treatment results are shown in table 2 below:
TABLE 2
As can be seen from Table 2, the total effective rate of the treatment group is 90%, and the difference is not significant compared with the control group, which indicates that the pharmaceutical preparation prepared from the poecilobdella manillensis can be used for treating leucoderma, and the effective rate of the pharmaceutical preparation reaches 90%.
In the treatment process, the Poecilobdella manillensis freeze-dried powder and the Poecilobdella manillensis ointment do not have any adverse reaction, while the methylprednisolone group has the common adverse reaction of glucocorticoid, such as body fluid and electrolyte disorder, digestive tract ulcer, endocrine disorder and the like, and particularly has very obvious adverse reaction after more than 1 treatment course, which shows that the Poecilobdella manillensis preparation is obviously superior to the glucocorticoid in treating leucoderma, and particularly can avoid various adverse reactions caused by the application of the glucocorticoid.
Taking the lyophilized powder of poecilobdella manillensis in example 1 as an example, typical case treatment is carried out, and the method and the result are as follows:
the following cases: a female is 65 years old, suffers from vitiligo for more than twenty years, has multiple symptoms on the whole body, especially has a left hand, and has no effect on multi-part treatment, the white spot condition on the left hand in 8 months in 2021 is shown in figure 1 before administration, and Poecilobdella manillensis lyophilized powder (0.3 g/bottle) is administered three times a day for 1 bottle/time. The white spot area is obviously reduced after one month, and the left-handed white spot condition is shown in figure 2 after three months of continuous administration, which indicates that the clinical cure is achieved.
The preferred embodiments of the present invention have been described above in detail, but the present invention is not limited thereto. Within the scope of the technical idea of the invention, many simple modifications can be made to the technical solution of the invention, including combinations of various technical features in any other suitable way, and these simple modifications and combinations should also be regarded as the disclosure of the invention, and all fall within the scope of the invention.
Claims (9)
1. Application of Poecilobdella manillensis in preparing medicine for treating vitiligo is provided.
2. The use of claim 1, wherein the method of treatment of the medicament comprises at least one of oral treatment and topical treatment.
3. The use according to claim 1 or 2, wherein the medicament is administered in an amount of 0.1 to 3 g/day.
4. Use according to claim 1, wherein the anti-thrombin activity of Poecilobdella manillensis is higher than 200U/g.
5. A medicinal preparation for treating leucoderma is characterized in that raw material components of the medicinal preparation contain poecilobdella manillensis and fructus psoraleae.
6. The pharmaceutical formulation of claim 5, wherein the Poecilobdella manillensis is provided in the form of at least one of lyophilized Poecilobdella manillensis powder, Poecilobdella manillensis salivary secretion, and Poecilobdella manillensis extract.
7. The pharmaceutical preparation according to claim 5 or 6, wherein the raw material components of the pharmaceutical preparation further comprise pseudo-ginseng, emblic leafflower fruit and longan.
8. The pharmaceutical formulation of claim 5, further comprising a pharmaceutically acceptable excipient.
9. The pharmaceutical formulation of claim 8, wherein the excipient is selected from at least one of sodium carboxymethylcellulose, glycerol, ethylparaben, laurocapram, polyethylene glycol 400, polyethylene glycol 4000, stearic acid, paraffin, and silicone cream.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210947163.5A CN115006431B (en) | 2022-08-09 | 2022-08-09 | Application of poecilobdella manillensis in preparing medicine for treating leucoderma and medicinal preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210947163.5A CN115006431B (en) | 2022-08-09 | 2022-08-09 | Application of poecilobdella manillensis in preparing medicine for treating leucoderma and medicinal preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115006431A true CN115006431A (en) | 2022-09-06 |
| CN115006431B CN115006431B (en) | 2022-11-11 |
Family
ID=83065418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210947163.5A Active CN115006431B (en) | 2022-08-09 | 2022-08-09 | Application of poecilobdella manillensis in preparing medicine for treating leucoderma and medicinal preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115006431B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115025127A (en) * | 2022-08-10 | 2022-09-09 | 云南三江本草药业有限公司 | Application of poecilobdella manillensis in preparation of medicine for treating chronic obstructive pulmonary disease and traditional Chinese medicine preparation |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1390573A (en) * | 2002-05-10 | 2003-01-15 | 谢庚安 | Chinese patent medicine for treating leukodema |
| CN101332270A (en) * | 2006-06-01 | 2008-12-31 | 刘伟 | External traditional Chinese medicine for treating vitiligo |
| CN101428060A (en) * | 2007-11-08 | 2009-05-13 | 北京蓝邦生物医学工程科技有限公司 | Traditional Chinese medicine preparation for treating leuoderma |
| CN101461847A (en) * | 2009-01-13 | 2009-06-24 | 牛付立 | Medicament composition for treating leukoderma |
| CN102908492A (en) * | 2012-10-24 | 2013-02-06 | 尹甲仑 | Traditional Chinese medicine composition for treating vitiligo and preparation method of traditional Chinese medicine composition |
| CN102988498A (en) * | 2012-10-13 | 2013-03-27 | 慈溪市锐玛电子有限公司 | Medicine composition for treating leucoderma |
| CN105194090A (en) * | 2015-10-27 | 2015-12-30 | 何江思 | Traditional Chinese medicine composition treating premature graying and vitiligo |
| CN107335035A (en) * | 2017-07-06 | 2017-11-10 | 王浩绪 | A kind of external application Chinese medicine for treating leucoderma |
| CN107496810A (en) * | 2017-07-15 | 2017-12-22 | 楚海龙 | A kind of Chinese medicine composition for treating leucoderma |
| CN109497563A (en) * | 2018-10-23 | 2019-03-22 | 上海奥医生物医药科技有限公司 | Leucoderma tailored version clinical nutrition formula and preparation method thereof |
-
2022
- 2022-08-09 CN CN202210947163.5A patent/CN115006431B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1390573A (en) * | 2002-05-10 | 2003-01-15 | 谢庚安 | Chinese patent medicine for treating leukodema |
| CN101332270A (en) * | 2006-06-01 | 2008-12-31 | 刘伟 | External traditional Chinese medicine for treating vitiligo |
| CN101428060A (en) * | 2007-11-08 | 2009-05-13 | 北京蓝邦生物医学工程科技有限公司 | Traditional Chinese medicine preparation for treating leuoderma |
| CN101461847A (en) * | 2009-01-13 | 2009-06-24 | 牛付立 | Medicament composition for treating leukoderma |
| CN102988498A (en) * | 2012-10-13 | 2013-03-27 | 慈溪市锐玛电子有限公司 | Medicine composition for treating leucoderma |
| CN102908492A (en) * | 2012-10-24 | 2013-02-06 | 尹甲仑 | Traditional Chinese medicine composition for treating vitiligo and preparation method of traditional Chinese medicine composition |
| CN105194090A (en) * | 2015-10-27 | 2015-12-30 | 何江思 | Traditional Chinese medicine composition treating premature graying and vitiligo |
| CN107335035A (en) * | 2017-07-06 | 2017-11-10 | 王浩绪 | A kind of external application Chinese medicine for treating leucoderma |
| CN107496810A (en) * | 2017-07-15 | 2017-12-22 | 楚海龙 | A kind of Chinese medicine composition for treating leucoderma |
| CN109497563A (en) * | 2018-10-23 | 2019-03-22 | 上海奥医生物医药科技有限公司 | Leucoderma tailored version clinical nutrition formula and preparation method thereof |
Non-Patent Citations (7)
| Title |
|---|
| "2017年《云南中医中药杂志》总目次", 《云南中医中药杂志》 * |
| AZAD HUSSAIN LONE等: "Leech Therapy- A Holistic Approach of Treatment in Unani (Greeko-Arab) Medicine", 《ANC SCI LIFE. 》 * |
| PANIGRAHI HEMANTA KUMAR等: "EFFICACY OF LEECH THERAPY AND AYURVEDIC COMPOUND IN VITILIGO：A QUASI EXPERIMENTAL STUDY", 《IJRAP》 * |
| 朱铁君: "常见色素性皮肤病的中西医结合治疗", 《中国医刊》 * |
| 穆静等: "四种含药血清对小鼠B16黑素瘤细胞黑素合成的影响", 《宁夏医科大学学报》 * |
| 陈思宏等: "白癜风制剂配合激素治疗进展期白癜风30例", 《陕西中医》 * |
| 陈琛等: "菲牛蛭体成分和养殖技术的研究进展", 《饲料工业》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115025127A (en) * | 2022-08-10 | 2022-09-09 | 云南三江本草药业有限公司 | Application of poecilobdella manillensis in preparation of medicine for treating chronic obstructive pulmonary disease and traditional Chinese medicine preparation |
| CN115025127B (en) * | 2022-08-10 | 2022-11-11 | 云南三江本草药业有限公司 | Application of poecilobdella manillensis in preparation of medicine for treating chronic obstructive pulmonary disease and traditional Chinese medicine preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115006431B (en) | 2022-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2489358B1 (en) | Oil-extracted product of indigo naturalis, and preparation process and use thereof | |
| CN115006431B (en) | Application of poecilobdella manillensis in preparing medicine for treating leucoderma and medicinal preparation | |
| CN111281966B (en) | Composition containing earthworm protein and preparation method and application thereof | |
| JPH05186360A (en) | Therapeutic agent for allergic disease and production of acanthopanax senticosus extract | |
| CN112516250A (en) | Traditional Chinese medicine composition for treating psoriasis vulgaris and preparation method thereof | |
| CN106668348A (en) | Pharmaceutical composition for treating diabetic retinopathy | |
| EP1539201B1 (en) | Antipyrotic and method of manufacturing the same | |
| CN112521389B (en) | Medicament and method for promoting wound healing | |
| US6660305B1 (en) | Composition for stimulating the synthesis of the melanic pigment and process for obtaining it | |
| CN112972536A (en) | A Chinese medicinal composition with hair growth promoting and hair blackening effects, and its preparation method | |
| CN110772590A (en) | Chinese medicinal compound preparation for treating verruca plantaris | |
| KR101048939B1 (en) | Method for producing product for promoting hair growth | |
| CN110075199A (en) | A kind of Chinese medicine composition and its preparation method and application for treating psoriasis | |
| CN115154533B (en) | Traditional Chinese medicine composition for treating chloasma and preparation method and application thereof | |
| CN115779028B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN109223931A (en) | A kind of burn cream and preparation method thereof for treating burn | |
| CN108671149B (en) | Traditional Chinese medicine composition for treating liver diseases and preparation thereof | |
| CN102793771B (en) | Preparation method of Tibetan drug for treating alopecia | |
| CN116832086B (en) | External traditional Chinese medicine composition for treating chapped skin and application thereof | |
| CN114984156B (en) | Pharmaceutical composition for treating chloasma | |
| CN114699484B (en) | Application of external skin care oil in preparing medicament for preventing and treating hemorrhoids | |
| CN109419941A (en) | The Chinese medicine composition and preparation method thereof that blood stasis swells and ache after a kind of set a broken bone | |
| CN105125990A (en) | Traditional Chinese medicine gel for promoting wound healing in lateral perineotomy | |
| CN115154360A (en) | Composition with whitening, freckle removing and moisturizing effects and application thereof | |
| CN105287696A (en) | Medicinal composition for treating childhood vitiligo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |